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abstract
The increasing demand for personalized cancer therapy requires a strong, intense,
and continuous collaboration between pre-clinical and clinical investigators. As
a part of the EORTC Translational Research Divison, the EORTC PathoBiology
Group (EORTC PBG), focuses on discovery and validation of cancer biomarkers,
providing both scientiﬁc evidence as well as quality assurance. The clinically
relevant target-identiﬁcation and validation studies carried out in the last decades
within the EORTC PBG represent a paradigm for EORTC studies in which laboratory
investigations on human biologic material are used to support the development
of drugs directed to deﬁned target molecules. The experience acquired within
the EORTC PBG with respect to standardization of cancer biomarker test kits
and reagents, quality assessment/assurance of cancer biomarker determinations,
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development of standard operating procedures for assessment of these markers
as well as instruction of methodologies and teaching of ethical issues represent
a valuable contribution of the EORTC PBG to the onco-translational strategies
of the EORTC.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
In recent years, the sharp increase in knowledge on the
mechanisms involved in tumor initiation and progres-
sion coupled with our understanding of the molecular
biology of cancer cells and the rapid development
of high-throughput technologies have broadened the
scenario of biological information related to speciﬁc
cancer cell alterations/functions which can integrate
clinico-pathological staging and the development of
novel effective therapeutics targeting speciﬁc molecular
pathways. These features are currently driving the
clinical need for planning molecular-based therapies, the
dawning of a new era of personalized cancer medicine
where selection of type and course of treatment can be
tailored to an individual’s disease and genotype. This1
innovative approach may not only increase therapeutic
efﬁcacy, but also decrease toxic side effects of cancer
therapeutics and reduce costs to society and health care
systems by avoiding ineffective or harmful treatments.
The most important message derived from decades
of translational research (TR) in cancer relies on
focusing on the clinically relevant needs, with a strong,
intense, and continuous collaboration between pre-
clinical investigators and physician scientists. Correct
assessment of patient status and therapeutic needs
may require the consistent and accurate determination
of key molecular parameters and takes advantage of
systematic preservation and access to biospecimens.
Studies on human specimens are essential in the
still ongoing process of discovering new mechanisms
involved in causing cancer or in determining its
progression, resistance/response to treatment, and thus
clinical outcome. In particular, independent molecularly
driven multicenter clinical studies form an important
link for validating the clinical relevance of cancer
biomarkers, thus bridging the translation of research
results into clinical practice. 2
The EORTC-PathoBiology Group (EORTC PBG), formed in
2006 from amerger between the former EORTC Pathology
Group and the EORTC Receptor and Biomarker Group
(RBG, operating since 1972 within the EORTC to provide
knowledge on the basics and clinical exploitation of
biomolecular markers/molecular signatures in tissue,
cells and bodily ﬂuids), is very active in the area of
discovery and validation of cancer biomarkers. 3
Optimization of opportunities to generate new hy-
potheses for TR deﬁnitely relies on a “round trip” model,
with a clinical translation of pre-clinical ﬁndings coupled
with pre-clinical investigations on information derived
from clinical trials. This pathway towards personalized
medicine is complex and warrants careful upfront
planning and input from a range of expertises. The
EORTC PBG supports the EORTC Translational Research
Division (TRD) and Disease-Oriented Groups (DOG) with
its basic science and clinical expertise to identify and
validate clinically relevant cancer biomarkers/molecular
signatures. The group members, with their expertise in
biochemistry, cellular and molecular biology, statistics,
pathology and clinical trials, are well grounded in
biobanking, pre-analytical/analytical testing and assay
performance as well as in statistical evaluation of
the test results needed for the integration of high-
quality biomarker assessment into clinical practice. In
fact, the repertoire of potential cancer biomarkers is
steadily increasing as is the variety of methods used
for their measurements, although their standardization
and quality control is often lacking as are guidelines
on interpretation of test results. This fact is not always
known to clinicians or to basic scientists, and even worse,
assay results from inadequately validated biomarker
studies are repeatedly being made available to the
public in scientiﬁc publications or promoted as com-
mercial products. Setting up quality-based guidelines
and informing the medically trained cancer researcher
represent a priority for the EORTC PBG.
2. Biomarker discovery and validation: recent
achievements of the EORTC PBG
TR is an essential component of the EORTC PBG
mission in order to assess and qualify the scientiﬁc
and clinical value of biomolecular markers/molecular
signatures in human biological materials (HBM), and to
carry out studies to provide relevant information for
patient management with high level of evidence for
clinical implementation. 4 Speciﬁcally, EORTC PBG has
been involved in TR activities focused mainly on solid
tumors, with the most prominent being cancer of the
breast, colorectum and ovary, and glioblastoma, in the
context of discovery and validation of function-related
biomarkers involved in oncogene or oncosuppressor
gene deregulation, cell cycle and apoptosis regulation,
DNA repair, extracellular matrix and neo-angiogenesis
features, cell progression and dissemination to other
organs in the body. Instrumental to the EORTC PBG
translational model are: (a) availability of well-annotated
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Fig. 1 – uPA/PAI-1 in primary breast cancer: an example of a successful development of a biomarker by the EORTC-
PathoBiology Group (formerly EORTC-Receptor and Biomarker Group).
and high-quality biological specimens from patients en-
tered clinical trials, through multicentric/multinational
intergroup collaborations; (b) establishment of standard-
ized, reproducible and robust assays to detect molecular
cancer biomarkers/signatures even on limited tumor ma-
terial; (c) quality assessment and assurance of reagents,
test systems (including pre-analytical processing and
post-analytical data processing), commercial kits and
equipments; (d) prospective planning of the study design
for the assessment of biologically and/or clinically
relevant biomarkers/signatures, according to national
regulatory and ethical issues.
The clinically useful PBG studies best suited to illus-
trate the translational strategy that leads from biomarker
identiﬁcation to assessment of its clinical beneﬁt are
the investigations on urokinase-type plasminogen acti-
vator (uPA) and its inhibitor (PAI-1, plasminogen activator
inhibitor type-1) in breast cancer (BC). 5 Following the
seminal retrospective observation on a small number
of cases made by Duffy et al. in 1988, 6 that women
whose BC presented at diagnosis with high levels of
uPA proteolytic activity had a high risk of developing
metastasis, independent but coordinated series of
preclinical investigations were initiated to assess and
qualify the clinical value of uPA and PAI-1 as predictors
of tumor invasiveness and metastatic potential, also
taking advantage of the complementarity expertise of
the EORTC PBG (then still the EORTC-RBG) members
(Fig. 1). Those initiatives included: (1) establishment
of a standardized, quality-assured immunometric assay
(ELISA) to determine uPA and PAI-1 antigen levels in
tumor tissue extracts 7; (2) pilot studies which conﬁrmed
the prognostic relevance of uPA and PAI-1 protein content
in a small number of prospectively collected tumor
specimens 8,9; (3) external quality assessment within the
EORTC-RBG framework of trans-European multicentric
uPA/PAI-1 antigen determination in human BC tissue
extracts, before converting it into a commercially avail-
able format 10,11; (4) prognostic relevance of uPA/PAI-1
conﬁrmed by multicentric studies carried out within
the EORTC RBG in large numbers of tumor specimens
analyzed retrospectively 12−14; (5) prognostic relevance
conﬁrmed in prospectively collected tumor specimens
and from an EORTC RBG pooled analysis of multicentric
studies comprising more than 8,000 BC patients in order
to get ready for a large clinical trial 7,15; (6) validation
of the clinical utility of the two biomarkers by a
prospective high-powered randomized chemotherapy
trial speciﬁcally identifying node-negative BC patients
who beneﬁt from chemotherapy, i.e., those with high
levels of uPA and/or PAI-1 (Chemo-N0, level-of-evidence 1
study carried out within the EORTC PBG framework, with
the participation of 14 different Institutions). 5,16
The outcome and impact of these studies are as
follows 5:
(1) uPA and PAI-1 were included in the guidelines
of the German Working Group in Gynecological
Oncology, AGO (since 2002 for prognostic assessment
in node-negative breast cancer), of the European Group
on Tumor Markers 17 (since 2005), of the American
Society of Clinical Oncology 18 (since 2007, “to
determine prognosis, for treatment planning and to guide
use of cyclophosphamide-methotrexate-ﬂuorouracil-based
adjuvant chemotherapy”) and of the National Academy
of Clinical Biochemistry Laboratory Medicine Practice
(since 2008) for use as biomarkers in BC manage-
ment 19;
ejc supplements 10, no. 1 (2012) 120–127 123
(2) two additional multicentric prospective clinical trials
in high-risk (uPA and/or PAI-1 high content) node-
negative BC patients 20 (NNBC-3: n=4149) or in HER2-
negative BC (Plan BTrial: n = 2484, in whichmolecular-
based risk is assessed according to Recurrence Score
and uPA/PAI-1) were activated and have recently
closed accrual;
(3) Phase I and II clinical trials with a small molecule
inhibiting uPA (WX-UK1) have been completed in
patients with BC and pancreatic cancer for which
promising results in terms of prolonged time to
progression and survival were reported. 21,22
Additional examples to summarize past and current
activities of the EORTC PBG for cancer biomarker dis-
covery associated to tumor progression and metastatic
potential include:
• development of “in vivo proof of concept” for tissue
inhibitor of metalloproteinases-1 (TIMP-1), including
prospective studies to evaluate the clinical signiﬁcance
of plasma levels for early recurrence in colorectal
cancer (CRC) and as a marker for minimal residual
disease in CRC and BC patients 23,24;
• investigations on molecular markers associated with
invasion and metastasis (kallikrein-related peptidases,
cathepsins in addition to other extracellular matrix
markers), 25 with hypoxia and angiogenesis (hypoxia-
inducible factor-1a, carbonic anhydrase IX), 26 and with
cell survival (apoptosis and telomere maintenance
mechanisms) 27 in different tumor types;
• identiﬁcation of gene expression signatures that
mediate BC metastasis in different sites (bone, 28
lung, 29 brain 30);
• identiﬁcation of microRNA signatures associated to
metastatization in speciﬁc BC molecular subtypes. 31
• Within this area of research, focused on biomarker
discovery associated with tumor progression, recent
efforts of PBG members have been dedicated to
evaluate new technologies for the detection and
molecular characterization of circulating tumor cells
in the peripheral blood of BC patients. 32
Once identiﬁed, biologically relevant cancer biomark-
ers/signatures of potential clinical interest enter the val-
idation pathway which generally involves multicentric
collaborations among PBG members.Within this context,
the following validation studies have been completed or
are in progress regarding:
• the Rotterdam 76-gene proﬁle for lymph node-negative
BC patients receiving local-regional treatment and/or
adjuvant tamoxifen 33,34;
• genomic and proteomic projects on different cancer
types to challenge gene signatures and epigenetic
biomarkers with patient’s prognosis and response to
chemo/endocrine therapy 35−37;
• studies on the DNA-methylation proﬁle of CpG islands
within promoter regions of candidate genes in BC and
brain tumors of patients subjected to different types of
systemic treatments. 38−40
In the context of the emerging scenario of personalized
cancer medicine, the EORTC PBG has recently focused
on pathway/target oriented strategies, with the develop-
ment of experimental models for in vitro–in vivo studies
and the establishment of functional studies for target
identiﬁcation and validation, also including targeting of
radioresistance-related pathways for the modulation of
radiation response.
3. EORTC PBG quality assessment and quality
assurance programs
For proper implementation of a biomarker in clinical
practice, an evidence-based consensus on its effective
clinical usefulness is needed. However, clinical studies on
biomarkers frequently report conﬂicting results. Among
the factors contributing to discrepancies among different
clinical studies are (1) lack of standardization of the
pre-analytical procedures, including tissue sampling/
collection, transport and processing in the laboratory;
(2) substantial differences in methodologic approaches,
test reagents and signal detection; (3) differences in
statistical methods employed, including determination
of cut-off points and weighting of the clinical impact
of biomarkers by uni- and multivariable analyses;
(4) heterogeneity of tissue architecture or molecular
structure/function.
The EORTC PBG Quality Assurance (QA) center in
Nijmegen has long-standing experience in this area,
starting in 1979 by performing QA studies on cancer
biomarkers both within and outside the EORTC. 41 Quality
assessment and assurance of the reagents and test
systems employed (including pre-analytical processing
and commercial kits for existing markers, and accounted
for collaborations with companies) 42,43 and of the
equipment used to quantify the expression level of
cancer biomarkers in tumor tissue extracts or in other
body ﬂuids still represent an important task of the
EORTC PBG.
The EORTC PBG regularly advises clinicians and
basic researchers on common methodologies for cancer
biomarker assays and ensures that appropriate external
quality assessment schemes are available. As most
of the phase II/III cancer trials involve multi-center
cooperation, special emphasis by the EORTC PBG is
placed on quality and performance of the assays, on their
reproducibility and on the collaboration with clinical
groups of the EORTC, with partners within framework
programs of the European Commission, with Health
Authorities and other national and international bodies
that have scientiﬁc and social interest in the supply of
optimal information about quality and performance of
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cancer biomarker tests and their relevance for cancer
patient management.
Guiding principles are provided and discussed on how
to inform physician scientists and cancer researchers
about quality control systems to enable a consistent
assessment of the clinical value of cancer biomarkers.
Knowledge on the good laboratory practice for tumor
tissue or blood sample collection and storage, tissue
processing, assay methods, reference materials, and
Standard Operating Procedures (SOP) is often missing.
Therefore, the EORTC PBG advises on procedures, test
kits and reagents to be utilized for cancer biomarker
determinations. Thus, the EORTC PBG takes an active
part in advising the EORTC-DOG regarding tissue/blood
storage and handling, cancer biomarker assessment,
SOPs, 44 biochemical/cellular methodologies and tech-
nologies as well on matters concerning good laboratory
practice, quality assessment and QA. The EORTC PBG is
therefore continuing to: (1) focus attention on cancer
biomarker development and clinical implementation,
including the development of test assays on archival
specimens 39 and/or on limited amount of tumor
material 45; (2) support high-level QA programs when
assessing cancer biomarkers. 46
The current portfolio of cancer biomarkers under
QA procedures by the EORTC PBG includes: (1) steroid
hormone receptors, invasion factors uPA and PAI-1 11
and oncogene HER2 in BC samples; (2) assessment of
circulating tumor cells in peripheral blood of cancer
patients; (3) development of internal and external ref-
erence materials for cancer biomarker assays; (4) writing
and communication of SOPs on specimen handling and
processing.
4. EORTC PBG translational strategies: biobanking
and biomarker qualiﬁcation
Access to HBM, such as tumor tissue, blood, ascitic
ﬂuid, saliva, urine and cell derivatives such as RNA
and DNA, in both sufﬁcient quantity and quality, is
considered a key element for cancer biomarker discovery,
validation and for molecularly driven clinical trial design
in order to achieve personalized treatment of cancer
patients. Clinical trials offer a unique opportunity to
collect HBM combined in a specialized setting that allows
prospectively designed, high-quality TR that would be
difﬁcult to obtain from community- or population-
based HBM collections alone. Increasingly, as the ﬁeld
advances towards individualized treatment of cancer
patients, access to HBM is becoming a necessity for
patient enrolment in a new generation of clinical studies
that are designed and driven by molecular hypotheses.
Hence, collection of HBM and its appropriate storage
in biobanks is critical for innovative translational and
clinical research, and failures/inefﬁciencies represent
major bottlenecks hindering successful bench to bedside
translation. Consequently, the EORTC has given priority
to setting clear guidance and policy for addressing
the challenges of pan-European HBM collection in
EORTC clinical studies and to maintain public trust in
biobanking for cancer research. 47 Within this context,
the EORTC PBG – based on the long-term experience and
expertise gained by its members who are often in charge
in their institutions of large biobanks, including well-
maintained frozen tumor tissues, with parallel parafﬁn
blocks and serum/plasma collections also linked to
clinical and follow-up databases – assisted EORTC with
a strong and intense collaboration between its members
and key persons of EORTC Translational Research Unit
and HeadQuarters (HQ) in developing strategies to
support the practical aspects of collection, storage, and
access to HBM. The ﬁrst version of the new policy
to regulate biospecimen collections in EORTC studies
was released in January 2011. The principles of the
new EORTC policy promote best practice in biobanking
and are in accordance with current international legal
and ethical standards for storage and future use of
HBM. Key topics covered include: (1) coordination of
the chain of custody of HBM collected from patients
enrolled in EORTC clinical studies; (2) ethical princi-
ples of coordinating trans-border collections of HBM;
(3) conﬁdentiality and data protection; (4) management
of and access to HBM; and (5) publication of resulting
research. To simplify TR integration and HBM collection
in clinical studies, the EORTC PBG supported the EORTC
in developing a checklist containing the key elements
of HBM collection set-up and combining these into a
simple tool for practical use. Through identiﬁcation and
managing of key risk areas, the success of HBM collection
can be maximized whilst achieving efﬁcient clinical trial
development. The EORTC PBG is also participating in
collaborations with other Societies and organizations,
notably the European Society of Pathology, to stimulate
the involvement of pathologists in EORTC clinical studies
and to assist with the biobanking and quality assurance
strategies.
5. EORTC PGB transfer-of-knowledge programs
Transfer-of-knowledge from EORTC PBG centers of excel-
lence to other EORTC groups represents an important
task, that can be achieved through: (1) transfer of
knowledge about cancer biomarker utility in the clinical
setting 48; (2) teaching various aspects of basic and
clinical research regarding biology and clinical impact
of cancer biomarkers and (3) transfer results on the
biological importance of cancer biomarkers obtained
in the research setting to the clinic (Fig. 2). The
complementary expertise of the various EORTC PBG
members makes them particularly suited to teach
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teaching and medical practice.
different aspects associated with the clinical utility of
cancer biomarkers, the different approaches for their
characterization, quantiﬁcation and validation, and the
quality assurance/assessment aspects. All these tasks
represent the main topics discussed at the annual
EORTC PBG meeting, and EORTC PBG members are
instructed at workshops, teaching classes and sym-
posia about methodological approaches and protocols
regarding the clinical implementation of important
cancer biomarkers. Furthermore, information is provided
regarding the design and execution of animal studies and
(pre)clinical trials, including ethical, legal, and societal
aspects of performing cancer research at the basic and/or
clinical level.
EORTC PBG members are organizing and participating
in the alternate annual EORTC–NCI–ASCO (ENASCO)
meetings in Brussels and the USA, and in the annual
tutorial for young clinical investigators held in conjunc-
tion with the ENASCO meeting. Moreover, continuous
knowledge exchange across the Atlantic is guaranteed
by a NCI liason ofﬁcer within the EORTC PBG. 46
6. Future strategies
Within the frame of the implementation program of
TR promoted by EORTC, EORTC PBG will contribute to
several aspects, including improvement of interactions
with DOGs and Network of Core Institutions (NOCI),
thus providing constant support to EORTC HQ for issues
concerning biobanking activity and review of TR studies/
protocols in order to stimulate ideas for research
and advice on HBM collections. At the same time,
EORTC PBG will assist EORTC in methodology validation,
by extending Quality Control programs to provide
support to EORTC TR trials, e.g., on circulating tumor
cells, RNA-based biomarkers and mutation analysis,
and for pathway/target oriented strategies, through the
availability of experimental models for in vitro–in vivo
studies, for target identiﬁcation and validation, and for
functional studies. In this complex scenario derived from
an increasing demand for individualized cancer therapy,
the experience acquired within the EORTC PBG during
several decades of collaboration among its members
will be of value for the process of incorporation
of cancer biomarkers into novel early clinical trial
designs. Eventually, this will allow optimal evaluation
of development of reﬁned monitoring techniques and
tools, biological assays and test reagents suitable for
in vitro and in vivo assessment of cancer biomarkers, and
will assure a high-quality laboratory infrastructure and
expertise with the capability to timely provide biological
readouts on HBM. To comply with the requirements
of the novel molecular medicine, an intensiﬁcation of
collaborations (Fig. 3) will be instrumental for a better
tailoring of EORTC PBG activities according to EORTC
needs. In keeping with this approach, in addition to
NCI and ASCO liaisons and to the participation of PBG
members on behalf of EORTC or of their own Institutions
in several European Union-funded framework projects
(including BBMRI and EurocanPlatform), the initiation of
new collaborations such as with the European Society
of Pathology (for a full integration of pathological issues
and investigations into contemporary clinical trials) and
with the Sanger Institute (for comprehensive proﬁling
of tumor somatic mutations, linking cancer biomarker
results with molecularly stratiﬁed clinical trials and
developing a molecular electronic record system to allow
patient access to forefront tailored treatments and to
foster the collaboration with pharma industries) will
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Fig. 3 – A network diagram illustrating the inter-
relationships among the EORTC PBG key areas of interest
(blue circles), as well as ongoing (grey circles) and in-
progress (red circles) collaborations.
126 ejc supplements 10, no. 1 (2012) 120–127
strenghten the participation of EORTC PBG in the EORTC
strategy and foster the collaboration of EORTC with the
pharma industry.
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